Summary:
In patients with alcohol use disorder and comorbid obesity, once-weekly semaglutide
significantly reduced alcohol consumption and body weight compared to placebo,
though it was associated with gastrointestinal side effects including nausea and vomiting.
| PICO | Description |
|---|---|
| Population | Adults with treatment-seeking alcohol use disorder and comorbid obesity. |
| Intervention | Once-weekly semaglutide injection (dose not specified in summary). |
| Comparison | Placebo injections administered once weekly. |
| Outcome | Semaglutide significantly reduced alcohol consumption and body weight compared to placebo. Treatment was associated with increased incidence of gastrointestinal adverse effects such as nausea and vomiting. |
Source: Klausen, Mette Kruse, et al. “Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.” Read article here.
